安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and . . .
DUBLIN, June 2, 2025 PRNewswire -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from the Phase 3 IMforte study of Zepzelca ® (lurbinectedin) in combination with atezolizumab (Tecentriq ®) as a first-line maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC), following induction
- Jazz Pharmaceuticals Announces Statistically Significant Overall . . .
DUBLIN, Oct 15, 2024 PRNewswire -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca ® (lurbinectedin) in
- Small Cell Lung Cancer Treatment | ZEPZELCA® (lurbinectedin)
ZEPZELCA ® (lurbinectedin) is a prescription medicine used to treat adults with a kind of lung cancer called small cell lung cancer (SCLC) You may also report side effects to Jazz Pharmaceuticals at 1-800-520-5568 Please see accompanying full Prescribing Information including Patient Information, and discuss with your doctor Contact Us
- Lurbinectedin Atezolizumab Combination Improves Survival in ES-SCLC
Jazz Pharmaceuticals announces statistically significant overall survival and progression-free survival results for Zepzelca (lurbinectedin) and atezolizumab combination in first-line maintenance
- Jazz Pharmaceuticals Pipeline
Currently, lurbinectedin is also being evaluated in combination with other agents for the following: • Phase 3 trial evaluating and comparing the activity and safety of lurbinectedin as a single agent and in combination with irinotecan in SCLC patients This trial is being conducted by PharmaMaras part of Jazz Pharmaceuticals’
- Lurbinectedin, Atezolizumab Combination Use in Extensive-Stage SCLC
Jazz Pharmaceuticals, Inc , recently announced positive top-line results from the phase III IMforte clinical trial The study evaluated Zepzelca (lurbinectedin) in combination with the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab (Tecentriq) compared with atezolizumab alone when administered as a maintenance treatment for adults with extensive-stage small–cell lung cancer (ES
- Jazz Pharmaceuticals, Inc. ZEPZELCA- lurbinectedin injection, powder . . .
ZEPZELCA- lurbinectedin injection, powder, lyophilized, for solution Jazz Pharmaceuticals, Inc -----HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZEPZELCA safely and To report SUSPECTED ADVERSE REACTIONS, contact Jazz Pharmaceuticals, Inc at 1-800-520-5568 or FDA at 1-800-FDA-1088
- Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq . . . - Nasdaq
--Jazz Pharmaceuticals plc today announced the U S Food and Drug Administration has accepted the supplemental New Drug Application for Zepzelca ® in combination with atezolizumab as a first-line
|
|
|